Evaluation of oxidative stress markers and cardiovascular risk factors in Fabry Disease patients

Autor(es)

Mueller, Karen B. ^[1] ; Galdieri, Luciano C. ^[1] ; Pereira, Vanessa G. ^[1] ; Martins, Ana M. ^[1] ; D'Almeida, Vania ^{[2, 1]}

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, Dept Pediat, BR-04024002 Sao Paulo - Brazil

^[2] Univ Fed Sao Paulo, Dept Psicobiol, BR-04024002 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: GENETICS AND MOLECULAR BIOLOGY; v. 35, n. 2, p. 418-423, 2012.
• Citações Web of Science: 8

Resumo

Fabry Disease, an X-linked inborn error of metabolism, is characterized by progressive renal insufficiency, with cardio and cerebrovascular involvement. Homocysteine (Hcy) is considered a risk factor for vascular diseases, but the mechanisms by which it produces cardiovascular damage are still poorly understood. Regarding the vascular involvement in FD patients, the analysis of factors related to thromboembolic events could be useful to improving our understanding of the disease. The aim of this study was to evaluate plasma Hcy and other parameters involved in the methionine cycle, as well as oxidative stress markers. The sample consisted of a group of 10 male FD patients and a control group of 8 healthy individuals, paired by age. Venous blood was collected for Hcy determination, molecular analysis, identification of thiobarbituric acid reactive substances, total glutathione and antioxidant enzymes activity, as well as vitamins quantification. Comparative analysis of FD patients versus the control group indicated hyperhomocysteinemia in 8 of the 10 FD patients, as well as a significant increase in overall glutathione levels and catalase activity. It is inferred that FD patients, apart from activation of the antioxidant system, present increased levels of plasma Hcy, although this is probably unrelated to common alterations in the methionine cycle. (AU)

• Processo FAPESP: 01/11366-9 - Estudo de determinantes bioquímicos e moleculares envolvidos no metabolismo da homocisteína em casos de homocistinúria e de defeitos cardíacos congênitos
• Beneficiário: Vânia D'Almeida
• Modalidade de apoio: Auxílio à Pesquisa - Regular